$MLTX earnings report

MoonLake's Q3 2026 release is a business-update filing for a clinical-stage company that reports no revenue. The results table shows operating expenses of $(79,852) thousand for the quarter, up from $(61,660) thousand in Q2 2026, and a net loss of $(79,545) thousand, up from $(61,805) thousand. Basic and diluted net loss per share was $(0.93), against $(0.84) in the prior quarter. Weighted-average shares rose to 85,380,482 from 73,915,296, so per-share loss moved less than the total net loss. No prior-year quarter is printed in the filing, so no year-over-year comparison is possible from the documents.

The increase in operating expenses is concentrated in R&D, which rose to $(68,871) thousand from $(50,221) thousand. The company states that the $18.7 million increase is primarily related to accrued milestone license fees for a regulatory milestone associated with the expected acceptance of the BLA submission. G&A was broadly flat, at $(10,981) thousand compared with $(11,439) thousand. Interest expense was $(2,655) thousand and other income, net was $3,593 thousand, leaving a pre-tax loss of $(78,914) thousand and an income tax expense of $(631) thousand.

On the balance sheet, cash and cash equivalents fell to $379,704 thousand from $477,905 thousand, while short-term marketable debt securities rose to $118,758 thousand from $59,125 thousand. The company reports total cash, cash equivalents and short-term marketable debt securities of $498.5 million as of September 30, 2026, and expects capital to fund operating expenses and capital expenditure into mid-2028. Long-term debt was $100,010 thousand, compared with $99,514 thousand at June 30, 2026. Total shareholders' equity declined to $381,628 thousand from $428,195 thousand, and the accumulated deficit widened to $(673,968) thousand from $(594,423) thousand. Share count rose to 85,106,685 from 83,606,685 and additional paid-in capital rose to $1,053,301 thousand from $1,021,980 thousand; the filing does not state the cause of either change.

On the regulatory and clinical side, the BLA for sonelokimab in moderate-to-severe HS was submitted on September 30, 2026. The company expects FDA notice of acceptance by the end of November 2026, a PDUFA date allocation and Priority Review decision by mid-December 2026, and a U.S. launch in H2 2027 if approved. IZAR-1 met all clinical endpoints at Week 16 for 60 mg with induction, and IZAR-2 completed enrollment with topline results expected in Q1 2027. The filing's boilerplate also restates that VELA-2's composite-strategy primary endpoint did not reach statistical significance (p=0.053).

The filing provides no financial guidance for revenue, margins or operating expenses, and no prior outlook was supplied, so no guidance comparison is made. The most important items for a reader are the BLA acceptance timing, the rising R&D line and its stated milestone-fee driver, the decline in cash and equity, and the 2027 readout calendar. The filing does not include a cash flow statement, so operating and free cash flow cannot be assessed from these documents.

MoonLake’s quarter was defined by positive Week 16 topline results from the Phase 3 IZAR-1 trial in biologic-naïve adults with active psoriatic arthritis. The company stated that the trial met all clinical endpoints for 60 mg sonelokimab. Reported responses included ACR50, ACR20, MDA and PASI90, with improvements also reported in HAQ-DI and SF-36 Physical Component Summary. The blinded safety analysis was consistent with previous clinical studies and identified no new safety signals.

The data disclosure is limited by the trial’s unblinding protocol. MoonLake disclosed absolute response levels and endpoint outcomes for the sonelokimab 60 mg with induction arm, but comparative analyses versus placebo and detailed treatment-arm data remain blinded until the Phase 3 program is complete. IZAR-1 also does not include a Standard of Care arm. The trial will continue through Week 52, with the company expecting the full readout in H1 2027.

Financially, MoonLake ended the quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities. Management expects this capital to fund operating expenses and capital expenditure requirements to mid-2028. The Hercules Capital debt facility also provides up to $400 million in additional non-dilutive funds for potential future funding needs.

Operating expenses reported in the release declined versus the prior quarter. Research and development expenses were $50.2 million for the three months ended June 30, 2026, compared with $54.5 million for the three months ended March 31, 2026. General and administrative expenses were $11.4 million versus $15.5 million, with the company attributing the decrease primarily to accelerated expense recognition in the prior quarter related to the voluntary cancellation of unvested stock option awards.

The next catalysts are execution milestones across the sonelokimab program. These include the expected HS BLA submission at the end of September 2026, the expected PDUFA date allocation and Priority Review decision at the end of November 2026, IZAR-2 enrollment completion in Q3 2026, PPP enrollment commencement in H2 2026, and P-OLARIS results at the end of 2026 or early 2027. The key data issue remains the eventual unblinding of comparative IZAR-1 results and the durability and safety information through Week 52.